Point72 Asia Singapore Pte. Ltd. purchased a brand new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) in the course of the 2nd quarter, HoldingsChannel studies. The fund purchased 2,053 shares of the biopharmaceutical firm’s inventory, valued at roughly $76,000.
A variety of different institutional traders additionally not too long ago modified their holdings of CLDX. Arizona State Retirement System elevated its stake in shares of Celldex Therapeutics by 2.0% within the second quarter. Arizona State Retirement System now owns 16,231 shares of the biopharmaceutical firm’s inventory valued at $601,000 after shopping for an extra 325 shares in the course of the interval. Los Angeles Capital Administration LLC elevated its place in Celldex Therapeutics by 9.5% in the course of the 2nd quarter. Los Angeles Capital Administration LLC now owns 7,371 shares of the biopharmaceutical firm’s inventory valued at $273,000 after buying an extra 638 shares in the course of the interval. CANADA LIFE ASSURANCE Co raised its holdings in Celldex Therapeutics by 26.4% in the course of the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical firm’s inventory value $192,000 after buying an extra 955 shares over the past quarter. Principal Monetary Group Inc. lifted its place in shares of Celldex Therapeutics by 10.0% within the 1st quarter. Principal Monetary Group Inc. now owns 13,153 shares of the biopharmaceutical firm’s inventory value $552,000 after buying an extra 1,194 shares in the course of the interval. Lastly, Fisher Asset Administration LLC boosted its stake in shares of Celldex Therapeutics by 6.2% within the 4th quarter. Fisher Asset Administration LLC now owns 21,812 shares of the biopharmaceutical firm’s inventory valued at $865,000 after buying an extra 1,274 shares over the past quarter.
Analyst Upgrades and Downgrades
CLDX has been the subject of a number of latest analyst studies. Stifel Nicolaus began protection on shares of Celldex Therapeutics in a report on Tuesday, June 18th. They issued a “purchase” ranking and a $58.00 goal worth on the inventory. HC Wainwright reissued a “purchase” ranking and set a $80.00 goal worth on shares of Celldex Therapeutics in a analysis report on Thursday, September twenty sixth. Wolfe Analysis lowered shares of Celldex Therapeutics from an “outperform” ranking to a “peer carry out” ranking in a report on Friday, September twenty seventh. Cantor Fitzgerald reiterated an “obese” ranking and set a $67.00 worth goal on shares of Celldex Therapeutics in a analysis observe on Monday, September sixteenth. Lastly, The Goldman Sachs Group initiated protection on Celldex Therapeutics in a report on Monday, September thirtieth. They set a “impartial” ranking and a $45.00 worth goal for the corporate. Two funding analysts have rated the inventory with a maintain ranking, 5 have issued a purchase ranking and one has assigned a robust purchase ranking to the inventory. In keeping with MarketBeat, Celldex Therapeutics at the moment has a consensus ranking of “Reasonable Purchase” and a median worth goal of $61.14.
Learn Our Newest Report on CLDX
Celldex Therapeutics Value Efficiency
Shares of CLDX inventory opened at $30.65 on Friday. The agency has a 50-day transferring common of $37.45 and a 200-day transferring common of $37.93. Celldex Therapeutics, Inc. has a one yr low of $22.11 and a one yr excessive of $53.18. The corporate has a market cap of $2.03 billion, a P/E ratio of -10.75 and a beta of 1.55.
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) final posted its quarterly earnings knowledge on Thursday, August eighth. The biopharmaceutical firm reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.05. Celldex Therapeutics had a destructive internet margin of 1,809.18% and a destructive return on fairness of 23.66%. The agency had income of $2.50 million in the course of the quarter, in comparison with analyst estimates of $1.13 million. As a gaggle, analysis analysts count on that Celldex Therapeutics, Inc. will put up -2.5 earnings per share for the present fiscal yr.
Celldex Therapeutics Firm Profile
Celldex Therapeutics, Inc, a biopharmaceutical firm, engages in growing therapeutic monoclonal and bispecific antibodies for the therapy of varied illnesses. Its drug candidates embrace antibody-based therapeutics to deal with sufferers with inflammatory, allergic, autoimmune, and different devastating illnesses.
Featured Articles
Wish to see what different hedge funds are holding CLDX? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report).
Obtain Information & Scores for Celldex Therapeutics Each day – Enter your e mail tackle beneath to obtain a concise day by day abstract of the most recent information and analysts’ rankings for Celldex Therapeutics and associated firms with MarketBeat.com’s FREE day by day e mail publication.
